Perla DiBerardino

BSN4-1

Feb. 5/14

GENERIC NAME

BRAND NAME

CLASSIF

ACTION

INDICATIO N

CONTRA INDICATION

SIDE EFFECTS

ADVERSE EFFECTS
CNS: seizures 1. 2.

NURSING INTERVENTION
Assess patient for infections Before initiating therapy, obtain a history to determine previous use of and reactions to penicillins. 3. Observe patient for signs and symptoms of anaphylaxis. Notify physician if it occurs. 4. Instruct patient to take medication around the clock at evenly spaced times and to finish medication completely, even if feeling better. 5. Advise patient to report signs of super infection (furry overgrowth o the tongue, loose or foul-smelling stools) and allergy. 6. Instruct patient to notify health care professionals if

Cefoxitin Sodium

Monowe ll

Anti infectives

Bind to bacterial cell wall causing cell death.

Treatment of intraabdominal and pelvic infection and for surgical infection prophylaxis; Endometritis ; Pelvic Inflammatory Disease; Gonorrhea

Hypersensitivity to cephalosporins; serious hypersensitivity to penicillins.

-changes in skin color -pain -swelling of the foot or leg -tenderness

GI: Pseudumembran ous colitis; nausea; vomiting; cramps Derm: Rasshes, urticaria Hemat: Bleeding, hemolytic anemia Misc: Allergic reactions including anaphylaxis

Perla DiBerardino

BSN4-1

Feb. 5/14

GENERIC NAME

BRAND NAME

CLASSIF

ACTION Binds to opioid receptors, inhibits

INDICATIO N

CONTRA INDICATION

SIDE EFFECTS CNS: dizziness, headache, somnolence, CNS stimulation, euphoria, seizure CV: vasodilation, tachycardia, orthostatic hypotension, hypertension GI: nausea, constipation, vomiting, dry mouth, anorexia, abdominal pain GU: Urinary retention/frequency , menopausal symptom SKIN: pruritus, rash, urticaria, vesicles

ADVERSE EFFECTS Change in consciousness awareness or responsiveness difficulty with breathing lack of muscle tone lightheadedness loss of consciousness pinpointed pupils of the eyes severe sleepiness shortness of breath slow or irregular heartbeat unusual tiredness

NURSING INTERVENTION -Assess pain location and type and give before pain becomes extreme -Check for urinary output that may be cause by urinary retention -Assess CNS changes such as dizziness, drowsiness and hallucinations -Assess for any allergic reaction -Encourage to increase oral fluid intake -To increase bulk in diet -Store drug in a cool environment -Raise the side rails -Assist in ambulation -Evaluate therapeutic response -Teach to report any symptoms of CNS changes

Moderate to severe pain Hypersensitivity; acute intoxication with any CNS depressant

Tramadol hydrochlorid e

Dolcet

Central Analgesi c

reuptake of norepinephrine, serotonin; does not cause histamine release or affect heart rate; not completely understood

Perla DiBerardino

BSN4-1

Feb. 5/14

GENERIC NAME

BRAND NAME

CLASSIF

ACTION

INDICATION

CONTRA INDICATION

SIDE EFFECTS

ADVERSE EFFECTS 1. Stomach or bowel bloating, ringing in the ears, vertigo, appetite increases or decreases, weight gain, muscle cramp/spasm, muscle pain/stiffness, numbness or tingling, anxiety, depression, decreases in mental sharpness, breathlessness, swelling of the face, skin rash or itchy skin,urinary tract infection

NURSING INTERVENTION Assess range of motion and pain in affected joints before and periodically throughout the therapy. 2. Assess patient for allergy to aspirin or NSAIDs. 3. Monitor AST and ALT levels. It may cause increase in AST and ALT levels. 4. 5. Monitor gum bleeding Monitor for any signs of hypersensitivity 6. 7. Administer with meals Instruct to avoid alcohol intake. It may cause bleeding

Etoricoxib

Arcoxia

(Therape utic) antirheu maticnon steroidal antiinflamma tory agent (Pharma cologic) COX-2 Inhibitor

It inhibits the enzyme cyclooxygenase 2 (COX-2) that is needed for the biosynthesis of prostaglandin.

Relief of acute pain

Weakness and Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic edema, urticaria or allergic-type reactions after taking acetylsalicylic acid or NSAIDs including cyclooxygenase2 (COX-2) inhibitors; severe hepatic dysfunction; estimated renal creatinine clearance <30 mL/min; children and adolescents <16 years; inflammatory bowel disease fatigue, dizziness, headache, flu-like illness, diarrhea, nausea, indigestion (dyspepsia), stomach pain or discomfort and dry mouth.

Perla DiBerardino

BSN4-1

Feb. 5/14

GENERIC NAME
Ketorolac Tromethamine

BRAND NAME

CLASSIF

ACTION

INDICATIO N

CONTRA INDICATION

SIDE EFFECTS

ADVERSE EFFECTS
-May increase 1. effects of oral anticoagulants , heparin, thrombolytics. -May effect of antihypertensi ves, diuretics. Salicylates, aspirin -may risk of GI side effects, bleeding. Bone marrow depressants -may risk of hematologic reactions. -May conc. toxicity of lithium. May methotrexate toxicity. 6. 5. 4. 3. 2.

NURSING INTERVENTION
Take only as directed; do not exceed prescribed dosage. May take with food/milk if GI upset occurs. Report if symptoms unrelieved. Drug may cause drowsiness and dizziness; avoid activities that require mental alertness until drug effects relieved. Avoid alcohol, ASA, and all OTC agents without approval. Report any unusual bruising/bleeding , weight gain, swelling of feet or ankles, increase joint pain, or change in urine patterns. Determine any liver or renal dysfunction; assess hydration. 7. Transient stinging, burning may occur

Ketanov

NSAIDS

Inhibits prostaglandin synthesis, reduces prostaglandin levels in Aqueos humor. Reduces intensity of pain stimulus reaching sensory nerve endings, reduces intraocular inflammation..

Short-term mngt. of moderate to severe acute pain

Asthma, hypovolemia, dehydration, history of peptic ulcer or Coagulation disease, hypersensitivity to NSAIDs, aspirin, prostaglandin synthesis i nhibitors, anaphylaxis,com plete or partial syndrome of nasal polyps, angioedema or bronchospasm , moderate to severe renal impairment, suspected or confirmed GI bleeding &/or cerebrovascular bleeding, hemorrhagic diathesis, high risk or incomplete hemo stasis.

-Bronchospasm, dyspnea, itching & rash. -Flatulence, indigestion nausea & diarrhea. -GI ulceration, bleeding & perforation may occur on longterm use. -Drowsiness, dizziness, headache, aseptic meningitis, convulsion, hallucination & hearing loss. -Inhibition of platelet aggregation, thrombocytopeni a & anemia. -Flank pain, fluid retention, oliguria, azotemia, nephritis. Rash &

Perla DiBerardino

BSN4-1
exfoliative dermatitis. 8.

Feb. 5/14
upon instillation. Monitor for signs of pain relief, such as an increased appetite and activity. 9. May cause nausea or vomiting (frequent mouth care, small, frequent meals, chewing gum, or sucking lozenges may help). 10. Maintain adequate hydration (2-3 L/day of fluids) unless instructed to restrict fluid intake.

Perla DiBerardino

BSN4-1

Feb. 5/14

GENERIC NAME

BRAND NAME

CLASSIF

ACTION Binds to opioid receptors, inhibits

INDICATIO N

CONTRA INDICATION

SIDE EFFECTS CNS: dizziness, headache, somnolence, CNS stimulation, euphoria, seizure CV: vasodilation, tachycardia, orthostatic hypotension, hypertension GI: nausea, constipation, vomiting, dry mouth, anorexia, abdominal pain GU: Urinary retention/frequency , menopausal symptom SKIN: pruritus, rash, urticaria, vesicles

ADVERSE EFFECTS Change in consciousness awareness or responsiveness difficulty with breathing lack of muscle tone lightheadedness loss of consciousness pinpointed pupils of the eyes severe sleepiness shortness of breath slow or irregular heartbeat unusual tiredness

Moderate to severe pain Hypersensitivity; acute intoxication with any CNS depressant

Tramadol hydrochlorid e

Dolcet

Central Analgesi c

reuptake of norepinephrine, serotonin; does not cause histamine release or affect heart rate; not completely understood

GENERIC NAME

BRAND NAME

CLASSIF

ACTION

INDICATIO N Relief of acute pain

CONTRA INDICATION

SIDE EFFECTS

ADVERSE EFFECTS Stomach or bowel bloating, ringing in the ears, vertigo, appetite increases or

Etoricoxib

Arcoxia

(Therape utic) antirheu maticnon steroidal anti-

It inhibits the enzyme cyclooxygenase 2 (COX-2) that is needed for the

Weakness and Patients who have experienced bronchospasm, acute rhinitis, fatigue, dizziness, headache, flu-like illness, diarrhea,

Perla DiBerardino
inflamma tory agent (Pharma cologic) COX-2 Inhibitor biosynthesis of prostaglandin. nasal polyps, angioneurotic edema, urticaria or allergic-type reactions after taking acetylsalicylic acid or NSAIDs including cyclooxygenase2 (COX-2) inhibitors; severe hepatic dysfunction; estimated renal creatinine clearance <30 mL/min; children and adolescents <16 years; inflammatory bowel disease

BSN4-1
nausea, indigestion (dyspepsia), stomach pain or discomfort and dry mouth. decreases, weight gain, muscle cramp/spasm, muscle pain/stiffness, numbness or tingling, anxiety, depression, decreases in mental sharpness, breathlessness, swelling of the face, skin rash or itchy skin,urinary tract infection

Feb. 5/14